 | | Vol. 6.10 – 18 March, 2022 |
| |
|
|
| Researchers investigated the role of X-box binding protein-1 (XBP1) in the progression of non-alcoholic steatohepatitis.
[Journal of Hepatology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators reported a functional impact of a splicing regulatory glutamine/lysine-rich protein 1 (SREK1) variant and its regulator, serine/arginine-rich splicing factor 10 (SRSF10), in hepatocarcinogenesis.
[Nature Communications] |
|
|
|
| The authors demonstrated that both therapeutic and preventative IL-23 blockade alleviated glucose intolerance, insulin resistance and protected against non-alcoholic fatty liver diseasedevelopment.
[Nature Communications] |
|
|
|
| Scientists explored the genomic and molecular underpinnings of HCC with increased fluorine-18 fluorodeoxyglucose uptake in positron emission tomography (PET) and identified therapeutic targets based on this imaging-genomic surrogate.
[Clinical Cancer Research] |
|
|
|
| Investigators identified DHX37 as one of the top RNA helicase genes with upregulated expression in HCC. DHX37 promoted proliferation of liver cancer cells in vitro and in vivo.
[Cancer Research] |
|
|
|
| Three metastasis-associated circRNAs identified in a previous circRNA-sequencing study were screened and validated in two HCC cohorts. CircRPN2 was downregulated in highly metastatic HCC cell lines and HCC tissues with metastasis.
[Cancer Research] |
|
|
|
| The authors demonstrated the involvement of hepatic stellate cell-derived hydrogen sulfide (H2S) in JNK/JunB mediated expression of TNFSF14 gene, which indicated that H2S played an important role in the regulation of HCC apoptosis.
[Cell Death & Disease] |
|
|
|
| Researchers established an in vitro long-term culture system that enabled stable proliferation and maintenance of human hepatocytes to ensure a constant supply.
[Stem Cell Research & Therapy] |
|
|
|
| The authors generated induced pluripotent stem cell (iPSC)-derived hepatocytes and iPSC-derived cholangiocytes cells and characterized them based on hepatocyte-specific and cholangiocyte-specific markers.
[Hepatology Communications] |
|
|
|
| Cultured progenitor cells established from primary hepatocytes of Pkdcc knockout mice produced a secretome, which promoted their own proliferation in 3D spheroids and proliferation of cultured fibroblasts.
[Journal of Cell Science] |
|
|
|
| Scientists demonstrated a liver-specific inhibition of lactate dehydrogenase (LDH) that resulted in a drastic reduction of LDH levels in the liver of primary hyperoxaluria 1 (PH1) and PH3 mice after a single dose delivery of AAV8 vectors expressing CRISPR/Cas9 system.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
| Researchers demonstrated that syntaxin11 (STX11), a member of the SNARE family, generally expressed in immune cells, mediated lipid metabolism by binding to adipose-triglyceride-lipase (ATGL) and inhibiting lipid droplet degradation and lipid autophagy in hepatocytes.
[iScience] |
|
|
|
| The authors demonstrated that in the liver tissues and Kupffer cells of diabetes mellitus patients and streptozotocin-induced hyperglycemic mice, the endoplasmic reticulum stress-ATF6-CHOP signaling pathway was activated.
[Cell Death Discovery] |
|
|
|
|
| Investigators summarize immuno-modulating drug-induced hepatitis B virus reactivation (HBVr) during rheumatoid therapy and its preventive strategies for HBVr-induced liver diseases, especially cirrhosis and HCC.
[Pharmacological Research] |
|
|
|
| Scientists summarize what we know about tumor-associated macrophages (TAMs) and HCC, discussing the roles of TAMs in HCC development and the possible approaches for TAMs-targeted therapy as potential targets for HCC treatment.
[Biochemical Pharmacology] |
|
|
|
| The authors review the evolution of tools to evaluate cancer stem cells in liver cancers, discuss their contributions and limitations, as well as their combined and complementary utilization with techniques like human tumor organoid culture.
[Carcinogenesis] |
|
|
|
|
| Exelixis, Inc. announced results from the final analysis of the second primary endpoint of overall survival from the Phase III COSMIC-312 trial, which evaluated cabozantinib (CABOMETYX®) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced HCC.
[Exelixis, Inc.] |
|
|
|
|
| May 1 – 4, 2022
Riviera Maya, Mexico |
|
|
|
|
|
| | Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| | Gilead Sciences – Foster City, California, United States |
|
|
|
| | Amsterdam UMC – Amsterdam, Netherlands |
|
|
|
| | NIH National Heart, Lung, and Blood Institute – Bethesda, Maryland, United States |
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
